|
[Related PubMed/MEDLINE]
Total Number of Papers: 9223
|
|
|
|
|
[Display Entries]
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
|
Page: of
|
|
|
|
| Abbreviation |
: MDS |
| Long Form |
: myelodysplastic syndrome |
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2023 |
A Late and Complex Presentation of Hereditary Haemochromatosis. |
HH, RAEB |
| 2 |
2023 |
A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. |
aGVHD, allo-HSCT, AML, CR, DLI, OS, PR, RFS, TRM |
| 3 |
2023 |
Acute Myeloid Leukemia in a Patient With Human Immunodeficiency Virus-Related High-Risk Myelodysplastic Syndrome. |
AIDS, AML, HIV |
| 4 |
2023 |
Advances in myelodysplastic syndromes: promising novel agents and combination strategies. |
HMA |
| 5 |
2023 |
Analysis of Immune-Cell Distribution of Bone Marrow in Patients with Myelodysplastic Syndrome. |
IPSS-R |
| 6 |
2023 |
Case report: Venetoclax therapy in a boy with acute myeloid leukemia in Shwachman Diamond syndrome. |
AML, HSCT, SDS |
| 7 |
2023 |
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. |
allo-HSCT, AML, R/R |
| 8 |
2023 |
Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience. |
AML |
| 9 |
2023 |
Clinical significance of prognostic nutritional index in myelodysplastic syndrome. |
OS, PFS, PNI |
| 10 |
2023 |
Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification. |
AML, ICC |
| 11 |
2023 |
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS registry study. |
EQ-5D-3L, GEE, HRQoL, OR, VAS |
| 12 |
2023 |
Diagnosis of immune pathophysiology in patients with bone marrow failure. |
AA, aAA, BM, HSCs |
| 13 |
2023 |
Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in BRAF and p.R461* in NF1 Genes-A Case Report with Literature Review. |
PD-L1, SqCC |
| 14 |
2023 |
Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes. |
CMP, GMP, HSC, HSPC, MEP, NBM, rhEPO, ROS, RS |
| 15 |
2023 |
Immune Complex Glomerulonephritis in a Patient with Myelodysplastic Syndrome with Ring Sideroblasts Treated with Luspatercept. |
AML, ESA, MDS-RS, MPGN, TGF-beta |
| 16 |
2023 |
Immunophenotypical profiling of myeloid neoplasms with erythroid predominance using mass cytometry (CyTOF). |
AEL, AML, LSC, MRD, PEL |
| 17 |
2023 |
Mesenchymal stromal cell senescence in haematological malignancies. |
AML, BM, BM-MSCs, CLL, MBL, MGUS, MM, SASP |
| 18 |
2023 |
Myelodysplastic syndromes, thy name is heterogeneity. |
ICC |
| 19 |
2023 |
Myeloproliferative Neoplasm and Myelodysplastic Syndrome-Associated Renal Disease: A Histopathological Report of Two Cases. |
MPN |
| 20 |
2023 |
On behalf of the SFGM-TC: prophylactic donor lymphocyte infusion in patients treated with allogeneic stem-cell transplantation for high-risk myelodysplastic syndrome and acute myeloid leukemia. |
allo-HSCT, AML, DLI, proDLI |
| 21 |
2023 |
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. |
--- |
| 22 |
2023 |
Successful azacitidine therapy for myelodysplastic syndrome associated with VEXAS syndrome. |
--- |
| 23 |
2023 |
T-replete cord transplants give superior outcomes in high risk and relapsed/refractory paediatric myeloid malignancy. |
AML, EFS, GVHD, HR, MRD, OS, R/R, SCT, TRM |
| 24 |
2023 |
The Impact of Mutation of Myelodysplasia-Related Genes in De Novo Acute Myeloid Leukemia Carrying NPM1 Mutation. |
AML, MFC, MMD, NGS, PCR |
| 25 |
2023 |
The value of serum IL-4 to predict the survival of MDS patients. |
CD, IL, OS |
| 26 |
2023 |
Treatment patterns in older patients with myelodysplastic syndromes: A population-based analysis reflecting the real world. |
CI, ESA, HMA, OS |
| 27 |
2023 |
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single cell resolution. |
GRN, HSPCs, scRNA-seq |
| 28 |
2023 |
[Acquired alpha-thalassemia in an 86-year-old patient with myelodysplastic syndrome]. |
ATMDS |
| 29 |
2023 |
[Recent advances in the treatment of myelodysplastic syndromes (MDS)]. |
--- |
| 30 |
2022 |
A Deep Learning Model for the Automatic Recognition of Aplastic Anemia, Myelodysplastic Syndromes, and Acute Myeloid Leukemia Based on Bone Marrow Smear. |
AA, AML, ASH, AUC, CI, CNN, NPV, PPV |
| 31 |
2022 |
A machine learning model of response to hypomethylating agents in myelodysplastic syndromes. |
AUROC, HMA |
| 32 |
2022 |
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. |
LR, RS |
| 33 |
2022 |
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignancies. |
AML, CMML, MAPK, MPN |
| 34 |
2022 |
A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes. |
FCSS |
| 35 |
2022 |
A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation. |
IPSS-R, MDS-RS, OS, WHO |
| 36 |
2022 |
A Pathogenic NRAS c.38 G>A (p.G13D) Mutation in RARA Translocation-negative Acute Promyelocytic-like Leukemia with Concomitant Myelodysplastic Syndrome. |
APL, RARA |
| 37 |
2022 |
A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. |
2-HG, AEs, AML, CR, IDH1 |
| 38 |
2022 |
A Phase 1/2 Study of the Oral Janus Kinase 1 Inhibitors INCB052793 and Itacitinib Alone or in Combination With Standard Therapies for Advanced Hematologic Malignancies. |
AML, DNMTi, JAK |
| 39 |
2022 |
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes. |
AML, CMML, LIC |
| 40 |
2022 |
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes. |
HI, HMA, IWG, OS, R/R, TI |
| 41 |
2022 |
A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. |
AML, GVHD, HCT, NK |
| 42 |
2022 |
A phase I/II open-label study of molibresib for the treatment of relapsed/refractory hematologic malignancies. |
AML, CTCL, NHL, ORR, RP2D |
| 43 |
2022 |
A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm. |
BRBs, HMAs, MDS/MPN, PBMCs |
| 44 |
2022 |
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations. |
AZA, IDA, LEN, VPA |
| 45 |
2022 |
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. |
AML, CMML |
| 46 |
2022 |
A Rare Case of Ankylosing Spondylitis Coexisting with Relapsing Polychondritis, Antiphospholipid Syndrome, and Myelodysplastic Syndrome. |
APS, AS, RP |
| 47 |
2022 |
A research review of experimental animal models with myelodysplastic syndrome. |
--- |
| 48 |
2022 |
A Systematic Literature Review of the Relationship between Serum Ferritin and Outcomes in Myelodysplastic Syndromes. |
SF, SLR |
| 49 |
2022 |
A Systematic Review of the Role of Runt-Related Transcription Factor 1 (RUNX1) in the Pathogenesis of Hematological Malignancies in Patients With Inherited Bone Marrow Failure Syndromes. |
AML, CMMT, CXXC4, FPD, GCSF3R, IBMFS, iPSCs, MeSH, WES |
| 50 |
2022 |
A treatment-refractory aggressive MDS-MLD with multiple highly complex chromosome 5 intrachromosomal rearrangements: a case report. |
--- |
| 51 |
2022 |
ABAT gene expression associated with the sensitivity of hypomethylating agents in myelodysplastic syndrome through CXCR4/mTOR signaling. |
GC-MS, HMAs |
| 52 |
2022 |
Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia. |
AML, DMRs, MSCs |
| 53 |
2022 |
Abnormal platelet immunophenotypes and percentage of giant platelets in myelodysplastic syndrome: A pilot study. |
FSC |
| 54 |
2022 |
Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022. |
ACS, AD, AH, AI, ALBU, ALD, AML, ARDS, ASAP, CDC, CNV, CSF, ctDNA, CyTOF, DESI, DFS, DHT, ECHA, EM, ER, FLVs, GBM, HCC, IGFBP-3, IGFBP7, IGFs, IHC, IND, LA, LOD, MAF, mAH, MALDI-TOF, MARS, MPN, MRM, NGS, NP, NPH, OS, p-Tau, PCR, PEEP, PG, PR, PSRBCT, Q-GRFT, RA, ROTEM, SEER, SLN, t-Tau, TB, TEG, TEM, TGF-beta, TNF, ToF-SIMS, UChicago, VET, VTM, YAP1, ZIKV |
| 55 |
2022 |
Acquired and hereditary bone marrow failure: A mitochondrial perspective. |
BMFS, HSC |
| 56 |
2022 |
Acquired spherocytosis in the setting of myelodysplasia. |
HS, NGS, RBC |
| 57 |
2022 |
Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. |
AML, IRAK4 |
| 58 |
2022 |
Adaptation of Serious Illness Care Program to be Delivered via Telehealth for Older Patients with Hematologic Malignancy. |
ACP, AML, EOL, SICP |
| 59 |
2022 |
Advance care planning in older patients with acute myeloid leukemia and myelodysplastic syndromes. |
ACP, AML, EOL, MOLST |
| 60 |
2022 |
Adverse events caused by cord blood infusion in Japan during a 5-year period. |
CBBs, CTCAE, ISBT |
| 61 |
2022 |
Agent Orange and dioxin-induced myeloid leukemia: a weaponized vehicle of leukemogenesis. |
AML, AO, TCDD, US |
| 62 |
2022 |
Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes. |
AML, KMT2A-PTD, NGS |
| 63 |
2022 |
Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study. |
allo-HSCT, DEC, GRFS, GVHD, OS, PFS |
| 64 |
2022 |
Allogeneic stem cell transplantation for patients with myelodysplastic syndromes. |
allo-HSCT, RIC |
| 65 |
2022 |
Allogeneic stem cell transplantation for trisomy 8-positive myelodysplastic syndrome or myelodysplastic/myeloproliferative disease with refractory Behcet's disease: Case report and the review of literature. |
allo-SCT, BD, TNF |
| 66 |
2022 |
Allogeneic transplantation for advanced acute leukemia. |
HCT |
| 67 |
2022 |
Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms. |
CSF3R, ESE |
| 68 |
2022 |
AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax. |
AML, TKI |
| 69 |
2022 |
Analysis of 5-Azacytidine Resistance Models Reveals a Set of Targetable Pathways. |
AML, AZA, HMA |
| 70 |
2022 |
Antisenescence effect of REAC biomodulation to counteract the evolution of myelodysplastic syndrome. |
AML, BMSCs, REAC, TO-RGN |
| 71 |
2022 |
Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. |
AML, DC, HMAs |
| 72 |
2022 |
Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS). |
CMML, IPSS, WHO |
| 73 |
2022 |
Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia. |
AML, CHIP, CRP, CVD, hs-CRP |
| 74 |
2022 |
Association Between Granulocyte Colony-Stimulating Factor (G-CSF) Use and Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Among Elderly Patients with Breast, Lung, or Prostate Cancer. |
AML, G-CSF |
| 75 |
2022 |
Association between transfusion status and clinical and economic outcomes in patients with myelodysplastic syndromes from the physicians' perspective. |
AML, ER, TD, TI, TS |
| 76 |
2022 |
Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. |
AA, ITP |
| 77 |
2022 |
Association of systemic inflammatory and autoimmune manifestations with myelodysplastic syndromes: A systematic review and meta-analysis. |
CI, SIAMs |
| 78 |
2022 |
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial. |
DA |
| 79 |
2022 |
Auer rods and faggot cells: A review of the history, significance and mimics of two morphological curiosities of enduring relevance. |
AML, MDS/MPN |
| 80 |
2022 |
Autoimmune disorders associated with myelodysplastic syndromes: clinical, prognostic and therapeutic implications. |
AD |
| 81 |
2022 |
Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis. |
allo-HSCT, AML, BM, CI, DLI, GVHD, OS |
| 82 |
2022 |
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors. |
AML, AZA, CR, DLI, EFS, HSCT, ORR, OS |
| 83 |
2022 |
Azacitidine Monotherapy in Patients With Treatment-Naive Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis. |
AEs, AZA, CR, DOR, OS, PR, RCTs, TTR |
| 84 |
2022 |
Beyond the routine CBC: machine learning and statistical analyses identify research CBC parameter associations with myelodysplastic syndromes and specific underlying pathogenic variants. |
AUC, CBC, ROC |
| 85 |
2022 |
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy. |
BGN, BM, BMBs, ECM, sAML |
| 86 |
2022 |
Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen. |
AML, MPN, MS |
| 87 |
2022 |
BMT for Myelodysplastic Syndrome: When and Where and How. |
allo-BMT, EMAs, ESAs, HMAs, HR, IMiDs, IPSS, IPSS-R, LR, MDAPSS, TRM, WPSS |
| 88 |
2022 |
Bone marrow CD3+ CD56+ regulatory T lymphocytes (TR3 -56 cells) are inversely associated with activation and expansion of bone marrow cytotoxic T cells in IPSS-R very-low/low risk MDS patients. |
BM, CTL |
| 89 |
2022 |
Bone marrow clonal hematopoiesis is highly prevalent in blastic plasmacytoid dendritic cell neoplasm and frequently sharing a clonal origin in elderly patients. |
BM, BPDCN, CH, CMML |
| 90 |
2022 |
Bone Marrow Fibrosis at Diagnosis and during the Course of Disease Is Associated with TP53 Mutations and Adverse Prognosis in Primary Myelodysplastic Syndrome. |
MF |
| 91 |
2022 |
Bone marrow fibrosis impact on response to azacitidine in myelodysplastic syndromes. |
--- |
| 92 |
2022 |
Bone marrow free immune checkpoints as a potential biomarker for differential diagnosis of acquired bone marrow failures. |
AA, ICUS, IST |
| 93 |
2022 |
Bone Marrow Immune Microenvironment in Myelodysplastic Syndromes. |
AML, HSCs, IME, MDSCs |
| 94 |
2022 |
Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes. |
AML, BMSCs, NK, TIGIT |
| 95 |
2022 |
Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes. |
BMME, ECM, GAG, HA, HR, HSPCs, LR, MSCs |
| 96 |
2022 |
Bone marrow-confined IL-6 signaling mediates the progression of myelodysplastic syndromes to acute myeloid leukemia. |
AML, DKO, IL-6R |
| 97 |
2022 |
CAISC: A software to integrate copy number variations and single nucleotide mutations for genetic heterogeneity profiling and subclone detection by single-cell RNA sequencing. |
CAISC, CNVs, scRNA-seq, SNVs |
| 98 |
2022 |
Case Report: A novel WRN mutation in Werner syndrome patient with diabetic foot disease and myelodysplastic syndrome. |
--- |
| 99 |
2022 |
Case Report: Coexistence of Multiple Myeloma and Auricular Chondritis in VEXAS Syndrome. |
MM |
| 100 |
2022 |
Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease. |
AIS |
|
A Search Service for Abbreviation / Long Form
